Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew Exogen 2000 Labeling For Non-Union Fracture Approved

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew will employ its 300-person direct sales force to promote an expanded indication for the Exogen 2000 low-intensity pulsed ultrasound device for treatment of non-union bone fractures, a market valued at roughly $110 mil.

You may also be interested in...



Exogen Registry Data "Minimally Acceptable" For SAFHS Medicare Coverage

Exogen's registry data and several well-controlled foreign studies were sufficient for the Health Care Financing Administration to approve the firm's request for national Medicare coverage for the Sonic Accelerated Fracture Healing System (SAFHS).

Exogen Registry Data "Minimally Acceptable" For SAFHS Medicare Coverage

Exogen's registry data and several well-controlled foreign studies were sufficient for the Health Care Financing Administration to approve the firm's request for national Medicare coverage for the Sonic Accelerated Fracture Healing System (SAFHS).

Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations

Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT013038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel